Paper Details

  1. Home
  2. Paper Details

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.

Author: , DeckerThomas, DegenhardtTom, FaschingPeter A, HarbeckNadia, HoffmannOliver, KatesRonald E, KümmelSherko, LüftnerDiana, MarschnerNorbert, MüllerVolkmar, OtrembaBurkhard, SchemChristian, SchinkötheTimo, SchmidtMarcus, SchumacherJohannes, TeschHans, ThomssenChristoph, UleerChristoph, WarmMathias, WitzelIsabell, WuerstleinRachel, ZaissMatthias

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This abstract discusses the importance of adherence to therapy in patients with metastatic breast cancer (MBC) who are receiving treatment with a cycline-dependent kinase 4/6 (CDK 4/6) inhibitor.
Paper Details　
Original Abstract of the Article :
Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 -) MBC, addition of targeted oral agents such as everolimus or a cycline-dependent kinase 4/6 (CDK ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193608/

データ提供：米国国立医学図書館（NLM）

eHealth in Breast Cancer: A Digital Oasis for Patient Care

In the world of oncology, the goal is always to improve patient care and outcomes. This study explored the potential of using eHealth, a digital platform for healthcare, to improve the quality of life for women with breast cancer. It is like creating a virtual oasis in the vast desert of cancer treatment, providing support and resources.

The study focused on women with hormone receptor-positive, HER2-negative breast cancer and investigated the impact of eHealth-based patient-reported outcome (PRO) assessment on their quality of life. The researchers designed a clinical trial to evaluate the effectiveness of this approach.

eHealth: A New Frontier in Breast Cancer Care

The findings suggest that eHealth-based PRO assessment can be a valuable tool for improving the quality of life for women with breast cancer. It allows for continuous monitoring of patient well-being and facilitates early detection and management of side effects.

Embracing Digital Tools

This research highlights the potential of eHealth to enhance the care and support provided to women with breast cancer. It underscores the need to embrace digital tools that can improve communication, monitoring, and overall patient experience.

Dr.Camel's Conclusion

This study demonstrates the transformative power of eHealth in improving the lives of women with breast cancer. It is a reminder that technology can be a powerful tool for enhancing patient care and empowering individuals in their healthcare journey.

Date :
  1. Date Completed 2023-05-19
  2. Date Revised 2023-05-20
Further Info :

Pubmed ID

37198674

DOI: Digital Object Identifier

PMC10193608

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.